Clinical operations and workforce strategy

The $97.41 Billion Clinical Trial Services Forecast and What It Means for Oncology

Compare the $97.41B clinical trial services forecast with the broader CRO market and see how oncology sponsors can use monitoring to resolve repeat site issues.

By Lampgen Clinical Research

· Updated

An illustrated CT scanner appears under “Three sites miss the same scan,” a hypothetical Phase III oncology scenario. The graphic shows a $97.41 billion global clinical trial services forecast for 2031.
AI-generated editorial illustration of a hypothetical Phase III oncology scenario. Market forecast by MarketsandMarkets.

3 min read · estimated

Sources
$66.20B$97.41B
Global clinical trial services market, 2026 estimate and 2031 forecast. Projected 8.0% compound annual growth.

What the source reported

MarketsandMarkets projects that the global clinical trial services market will grow from $66.20 billion in 2026 to $97.41 billion in 2031, an 8.0% compound annual growth rate. Site management and monitoring led its 2025 service categories, Phase III accounted for about 39.5% by trial phase, and oncology led by therapeutic area. For oncology sponsors planning larger multicenter studies, the report points to a specific budget question. Where would additional monitoring capacity protect a protocol requirement or help a site resolve an issue sooner? [1]

The publisher estimates that North America accounted for roughly 45% of the 2025 market. Small molecules represented 50.5% of spending by modality. Full-service outsourcing had the largest share among delivery models, alongside functional service and hybrid arrangements. These are separate views of the 2025 market. The projected increase is a revenue estimate. Spending can rise through greater study volume, more services per study or higher service costs. Trial starts, access and evidence quality each require their own measures. [1]

The same publisher’s broader contract research organization (CRO) services report estimates $93.02 billion in 2026 and $140.32 billion in 2031, with 8.6% compound annual growth. That analysis groups CRO offerings across early-phase, clinical, laboratory and consulting services. The $97.41 billion forecast covers clinical trial services such as monitoring, recruitment, laboratory work, pharmacovigilance and biostatistics. The two studies use different market definitions, so treat each as a separate estimate. [1, 2]

What this means for trial teams

Investigate across sites. Imagine three sites miss a required baseline imaging window in a Phase III oncology study. A clinical research associate (CRA) can verify scheduled and actual dates against the protocol, then compare booking lead times, imaging vendor capacity and who owns the scheduling handoff. Shared causes and site-specific causes call for different responses. Follow the study’s escalation process and the investigator’s direction for participant-level decisions.

Give the response an owner and a measure. Lampgen’s SIGNAL™ framework helps study teams investigate the pattern, assign an action and see whether it worked. If a shared booking process is the bottleneck, identify who can change that process. At the next review, compare the percentage of required baseline scans completed on time at each site, using the number due as the denominator. Record whether patients needed a repeat trip and whether the issue recurred after the change.

Put oversight in the outsourcing agreement. ICH E6(R3), issued as FDA final guidance in September 2025, describes oversight proportionate to trial risk and calls for timely escalation and follow-up. The sponsor retains ultimate responsibility for its trial-related activities when it assigns work to a service provider. Agree on who reviews cross-site findings, who can authorize a workflow change and what the evidence of resolution will look like. [3]

Hire for the study in front of you. In an oncology CRA interview, give the candidate the same baseline imaging scenario. Ask what records they would compare, how they would distinguish a shared workflow problem from a site-specific issue and when they would escalate. Verify that their experience fits the protocol and phase. Lampgen Clinical Research helps sponsors and CROs match oncology CRA experience to those responsibilities.

Budget for participation during site feasibility. Ask coordinators and imaging teams how patients will reach screening appointments, whether visits can be combined where the protocol permits, and what support is available for transport and language access. Track screening attrition and repeat visits so the study team can see which barriers persist. FDA’s final participation guidance discusses how eligibility, enrollment practices and trial design can help enroll a population that better reflects intended patients. [4]

Sources

  1. MarketsandMarkets — Clinical Trial Services Market, Global Forecast to 2031
  2. MarketsandMarkets — CRO Services Market, Global Forecast to 2031
  3. FDA — ICH E6(R3) Good Clinical Practice, final guidance (September 2025)
  4. FDA — Enhancing Participation in Clinical Trials, final guidance (December 2025)

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?